Business context and reporting period
Filing identity: The supplied filing is Synthetic Biologics, Inc.’s Form 10-K for the fiscal year ended December 31, 2019, filed February 20, 2020. This does not match the request metadata naming Theriva Biologics, Inc. or describing the period as “2019 Q4.” The filing reports annual results, not standalone fourth-quarter results.
Synthetic Biologics was a clinical-stage biotechnology company developing microbiome-focused therapies. Its lead programs were SYN-004 for antibiotic-related microbiome damage and potential prevention of C. difficile infection (CDI) and complications in transplant patients; SYN-010 for IBS-C; and early-stage SYN-020. SYN-006, SYN-007 and SYN-005 were earlier-stage programs. The company had no approved products and reported very limited revenue historically.
Financial performance and position
| Metric | FY 2019 | FY 2018 |
|---|---|---|
| Revenue | No material product revenue reported | No material product revenue reported |
| Research and development expense | $11.1 million | $11.8 million |
| General and administrative expense | $4.6 million | $5.7 million |
| Operating loss | $15.7 million | $17.6 million |
| Other income | $0.3 million | $4.2 million |
| Net loss | $15.4 million | $13.4 million |
| Net loss attributable to common stockholders | $16.1 million | $25.3 million |
| Loss per common share | $0.98 | $4.06 |
| Cash used in operating activities | $13.9 million | $17.3 million |
Cash and cash equivalents were $15.0 million at year-end, down from $28.9 million. Current assets were $16.4 million and current liabilities $5.3 million. Total liabilities were $5.7 million, including $0.7 million of lease liabilities; the filing does not identify conventional borrowings as a material balance-sheet item. Accumulated deficit was $235.5 million, and total stockholders’ equity was a deficit of $1.1 million. No meaningful margin analysis is available because the company had no material product sales.
The independent auditor issued an unmodified opinion on the financial statements but included a going-concern explanatory paragraph, citing recurring losses and net capital deficiency that raise substantial doubt about the company’s ability to continue without additional capital.
Changes versus the prior year
- Operating expenses fell by about $1.9 million. R&D declined 6%, primarily reflecting lower SYN-004 indirect costs and the absence of an active SYN-004 clinical trial during 2019; increased SYN-020 manufacturing and IND-enabling toxicology costs partly offset the decrease. G&A declined 19%, including lower stock-based compensation and professional and investor-relations costs.
- Net loss increased by about $2.0 million, despite lower operating expenses, because 2018 included $4.1 million of noncash income from the change in fair value of warrant liabilities; 2019 had no comparable gain and only $0.3 million of total other income.
- Loss attributable to common stockholders and per-share loss improved substantially versus 2018, largely because 2018 included $11.7 million of Series B preferred-stock discount accretion and related deemed dividends, compared with $0.5 million in 2019. This was not an improvement in operating profitability.
- No financing proceeds were raised in 2019. In 2018, the company received approximately $16.9 million net from a public offering and $12.2 million net through its at-the-market program.
Outlook, commentary and key risks
- Funding and runway: Management stated that existing cash was expected to support overhead, limited research and specified activities, including the ongoing SYN-010 Phase 2b study, the planned SYN-004 transplant-patient study and SYN-020 IND preparation. The filing also says the company lacked sufficient capital beyond the next 12 months and needed further financing. Management’s runway statements are not fully consistent: one passage says cash could execute plans through December 31, 2020, while another says cash would not be sufficient for the next twelve months. There were no committed financing sources.
- Clinical plans: SYN-004’s proposed CDI Phase 3 program was contingent on financing or a strategic partnership; estimated completion costs exceeded $80 million. The company planned to begin a Washington University Phase 1b/2a SYN-004 study in up to 36 allogeneic HCT recipients in Q2 2020, subject to regulatory and institutional approvals. A Phase 2b/3 SYN-010 registration program was also deferred pending financing; an investigator-sponsored Phase 2b study was enrolling, with a readout anticipated in the first half of 2020. SYN-020’s IND filing was anticipated in Q2 2020.
- Development uncertainty: The SYN-010 investigator-sponsored study experienced higher-than-expected screen failures because of its methane eligibility threshold; investigators could conduct a blinded interim or futility analysis. Management also noted potential for SYN-010 development in methane-positive chronic idiopathic constipation, based on a commercial assessment, but this was exploratory.
- Other risks and contingencies: The company relied on third-party manufacturers, generally a single manufacturer for each lead candidate, and on external clinical and research partners. Clinical efficacy and safety remain unproven at registration stages; regulatory approval, patient enrollment, manufacturing scale-up, reimbursement and commercialization are uncertain. Further equity or convertible financing could dilute shareholders. The NYSE American had notified the company of stockholders’ equity noncompliance; it accepted a compliance plan through November 25, 2020, with delisting possible if requirements or plan progress were not met. A former chief medical officer had asserted “good reason” to terminate an employment agreement; the company disputed aspects of the claim. No material legal proceedings were reported.
Most important facts for investors to verify
- Confirm the issuer and reporting period: the filing is Synthetic Biologics’ FY 2019 10-K, not a Theriva Biologics filing or a quarterly report.
- Reconcile the company’s differing statements about whether $15.0 million of year-end cash covers the next twelve months, and identify subsequent financing or cash-burn developments.
- Check progress on NYSE American listing compliance and any resulting effects on access to capital and trading liquidity.
- Verify whether anticipated clinical milestones occurred, particularly the SYN-004 transplant study, SYN-010 Phase 2b readout and SYN-020 IND filing, and whether additional financing or partnerships were secured.
- Assess potential dilution and capital structure, including preferred stock, warrants, options and CSMC’s conditional exchange rights.